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Laboratory measurements of hemoglobin A1c above 6.5% were approved as an additional diagnostic criteria for
diabetes mellitus by the American Diabetes Association in 2010. Several recent pediatric studies have cast HbA1c
measurement in children in an unfavorable light in the pediatric population, by comparing HbA1c measurements
to results on oral glucose tolerance test (OGTT) or fasting plasma glucose (FPG). However, many of these studies do
not recognize that diabetes diagnostic criteria are based upon long-term health outcomes. In this sense, OGTT and
FPG have themselves never been validated in the pediatric population. Studies to validate diagnostic tests for
diabetes in pediatric populations may take a substantial period of time, and may prove unfeasible. However, studies
that tie diagnostic results as a child to diagnostic results as an adult may be more feasible and may provide the
data needed to determine which pediatric diagnostic criteria to use. Thus, for the time being, except for cases of
hemoglobinopathy, cystic fibrosis, and a few other exceptions, describing HbA1c as ‘lacking in sensitivity or
specificity’ in the pediatric population because of lack of correlation with OGTT is not scientifically sound.
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This paper is a commentary from the Pediatric Endo-
crine Society Drugs and Therapeutics Committee. Its
goal is provide background information and guidance to
both pediatric endocrinologists, and also to primary care
practictioners on the current use of HbA1c for the diag-
nosis of Type 2 diabetes in children. In addition, it has
the goal of pointing out some of the flaws in current
methodologies being used to address this question.
Diagnostic criteria for diabetes were initially was based
on variation from normal [1]. As information about the
degrees of glycemia that lead to diabetic complications
became available, criteria were revised. In 1997, the
Expert Committee on Diagnosis and Classification of
Diabetes Mellitus examined population data for retin-
opathy, and noted that for Fasting Plama Glucose (FPG),
2-hour postload glucose during an oral glucose toler-
ance test (OGTT), and hemoglobin A1c (HbA1c), the
diabetes-related complication of retinopathy increased
linearly above a certain cutpoints; for FPG and OGTT,* Correspondence: ckapadia@phoenixchildrens.com
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distribution, and reproduction in any mediumthose cutpoints became the basis for the diagnosis of
diabetes [2].
In 2010, it was felt that with the increasing adherence
to the National Glycohemoglobin Standardization Pro-
gram (NGSP), laboratory-based HbA1c is measured in a
standardized fashion in the majority of labs in the U.S.
Furthermore, the American Diabetes Association (ADA)
noted that review of epidemiologic data supported a re-
lationship between HbA1c and the risk of retinopathy
similar to what had been shown for FPG and OGTT.
Thus, in 2010, the ADA added A1c of 6.5 percent or
greater as a diagnostic criterion [3].
The ADA required that a laboratory-based HbA1c
assay method certified by the NGSP be used. This
ensures that the assay used is standardized or traceable
to the Diabetes Control And Complications Trial [4,5].
Obtaining screening laboratories for diabetes in the at-
risk population has long been established practice in
adults. However, in the pediatric population, data have
thus far largely been extrapolated from adult studies,
and screening practices vary. The issue has become
more pertinent with the rise of pediatric obesity. While
FPG and OGTT thresholds, as extrapolated from adult
populations, have largely been accepted by the communityentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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tion of use of HbA1c has met resistance.
Main text and discussion
An important benefit of use of HbA1c is that patient
does not need to be fasting, and testing does not require
a return visit [6]. HbA1c has less variability and is more
reproducible than FPG and OGTT [7].
However, HbA1c also has several potential disadvan-
tages. Hb A1c may miss cases of Type 1 diabetes in
which hyperglycemia develops over a short period of
time. Furthermore, HbA1c is not a perfect estimation of
mean blood glucose, and varies by ethnicity [8,9]. In
addition, diseases such as iron deficiency anemia, sickle-
cell disease, thalassemia, and other hemoglobinopathies,
can alter HbA1c [10].
Recent studies
When FPG was used to diagnose diabetes, HbA1c of
6.5% had sensitivity of 75.0% and specificity of 99.9%
[11]. The authors examined the diagnosis of pre-diabetes
noted a low sensitivity but a good specificity (98.3%) for
a HbA1c of 5.7%, and also for HbA1c of 6.0% (specificity
99.4%).
Another study [12] compared HbA1c to OGTT in
over 1000 obese patients and concluded that A1c has
low sensitivity and specificity for diabetes when diabetes
is defined by OGTT results; 9 of 893 patients with an
HbA1c less than 5.7% were determined to have diabetes
using OGTT criteria. In addition, a larger number of
cases of prediabetes defined by OGTT were not identi-
fied using an HbA1c cut-off of 5.7%; 240 of the 347
(69%) cases of prediabetes in this high-risk population
had HbA1c <5.7%.
In a smaller study, HBA1c cut-off of 6.5% had a sensi-
tivity of 40% and a specificity of 96% in accurately diag-
nosing patients with type 2 diabetes, when using OGTT
as a gold standard [13].
A study of 254 overweight or obese adolescents also
raised questions about HbA1c use for diagnosis [14]. In
this study, there were 99 (39%) cases of prediabetes and
3 (1.2%) cases of diabetes using FPG and OGTT as gold
standards. Test performance was assessed using receiver
operating characteristic (ROC) curves and calculations
of area under the ROC curve (AUC). HbA1c (AUC 0.54
[95% CI 0.47-0.61]) displayed poor discrimination for
identifying children with dysglycemia that had been
identified on OGTT. In fact, in this study, random glu-
cose (AUC 0.66 [0.60-0.73]) had better correlation with
OGTT.
The potential advantages of use of HbA1c, however,
were born out by a study before and after a change in
recommendation to allow use of HbA1c in screening
of adolescents [15]. Rates of screening for diabetesincreased from 39 to 47% as a result, and this led to
twice as many incident T2DM diagnoses during a simi-
lar time period. HbA1c threshold of 6% indicated pro-
gression to diabetes in 18% of patients, while the 5.7%
threshold resulted in only 1.3% progression to diabetes,
over about 3 years . In a separate study with 468 sub-
jects, HbA1c cut-off of 6% had greater correlation with
OGTT results than A1c threshold of 5.7% [16]. This
study showed sensitivity and specificity of 86% and 85%,
respectively, for HbA1c threshold 5.7%, but 99% and
96%, respectively, for HbaA1c threshold of 6%.
Comparing unvalidated methodologies: a pitfall of
many studies
Studies that compare HbA1c to other methods of diag-
nosing diabetes in pediatric populations are handicapped
by the fact that the other methods – FPG and OGTT –
are themselves not validated in the pediatric population.
A truly validated definition of diabetes in pediatric popu-
lations requires insight into the relationship of the pro-
posed definitions to relevant aspects of medium and
long-term health [17].
Assuming that OGTT or FPG are better than HbA1c
for determining risk of complications is unfounded; in
adults, even though HbA1c, FPG, and OGTT are often
discrepant in individuals, all 3 markers are shown to cor-
relate very well with risk of complications [2,3].
Conclusions
The diagnostic thresholds of glycemia in the adult popu-
lation were formulated because these are theh thresholds
at which retinopathy increases. Such thresholds have
never been defined in the pediatric population. In this
sense, for diagnosis of diabetes in asymptomatic or min-
imally symptomatic children, there are no validated
methodologies. OGTT, which is being used as a ‘gold
standard’ in many studies, in addition to lacking valid-
ation as noted above, also suffers from having low repro-
ducibility [18]. Therefore, dismissal of HbA1c 6.5% or
greater for diagnosis of diabetes at this time, because of
lack of correlation with OGTT, is a flawed approach.
The lack of correlation between studies has already
been acknowledged and discussed in adult populations,
including in the ADA’s clinical practice guidelines [3,4].
While the correlation appears to be lower in pediatrics,
it is not yet clear which of the studies, if any, are ‘faulty,’
and obtaining such data would require comprehensive,
multi-center, long-term studies on incidence of retinop-
athy; such studies appear unlikely to occur at this time.
Therefore, conclusions that dismiss HbA1c use for the
diagnosis of diabetes in children are based on incom-
plete data. Considering that the demographics of Type 2
diabetes skew towards disadvantated populations, we
should not dismiss a valuable, flexible tool that, put into
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detection of this disease [15].
Recommendations
1. ADA criteria for the diagnosis of diabetes, though
formulated from data in adults, are useful for
screening the asymptomatic, or minimally
symptomatic, at-risk pediatric population at this
time, and this includes the ADA’s more recent
recommendations regarding HbA1c.
2. When test results do not correlate with each other,
or appear to give information conflicting to the
clinical situation, practictioners must use clinical
judgement. Amongst FPG, OGTT, or HbA1c, one
test is not validated to a greater extent than another
in the pediatric population.
3. There are some questions about HbA1c use in those
with cystic fibrosis [19], though some data shows it
may be useful [20].
4. HbA1c is likely reliable in those with sickle-cell
carrier status, as long as an assay without
interference from abnormal hemoglobins is used
[5,21]. HbA1c is not reliable in those known to have
a hemoglobinopathy or any other disorder resulting
in significant increases in red blood cell turnover, or
in pregnancy [22]. Assay interference information is
available on the NGSP website [5].
5. Laboratory-based hemoglobin A1c using a
methodology and assay certified by the National
Glycohemoglobin Standardization Program is the
preferred method for diagnostic purposes [3-5].
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